Metabolism Drugs Market by Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, Drug Therapy, Others), by Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Latin America, and MEA) and forecast to 2029

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Metabolism Drugs market was valued at USD 7,098.9 million in 2022 and is expected to grow at a 5.42% CAGR from 2023 to 2029. Metabolism is the process of breakdown of food in the body to various proteins, carbohydrates, and fat. The metabolism may be affected due to lack of production of enzymes in the body. Metabolism drugs are used to treat metabolism disease as a result of improper or inadequate or malfunctioning of metabolism process in the body. Metabolism disease can also be caused by genetics. The genetically caused metabolism disease has less incidence and prevalence rate. Metabolic diseases include hereditary tyrosinemia, Gaucher disease, hereditary orotic aciduria, and Fabry disease. Increasing prevalence of metabolic disorders, and rising awareness among the public about treatment and diagnosis of various metabolic disorders is expected to drive the growth of metabolic drugs market over the forecasted years. In addition, presence of several risk factors like obesity, presence of comorbidities, and growing unhealthy lifestyle is expected to boost the growth of metabolism drugs market. Furthermore, increasing development of analytical tools along with research and development of new drugs are expected to trigger the metabolism drugs market growth. For instance, researchers in University Hospitals Cleveland Medical Centre discovered a hormone called asprosin, which stimulates appetite and increases blood glucose levels by acting on the hypothalamus and the liver in human body. However, the side effects caused by the prolonged treatment along with the clinical hold on trails by market players is expected to hinder the market growth of metabolism drugs market over the forecasted years. For instance, in June 2022, Astellas Pharma, Inc. announced that the USFDA has placed a hold on the FORTIS phase1/2 trial following the occurrence of serious adverse effects. Geographically, North America region held the major market share in 2022 and is expected to dominate the global metabolism drugs market in the forecasted years.

Metabolism Drugs Market Key Developments:
In November 2020, USFDA approves the first drug ‘oxlumo’ to treat rare metabolic disorder-primary hyperoxaluria type 1.

Metabolism Drugs Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Metabolism Drugs Market Dynamics

Metabolism drugs market is expected to grow over the forecasted period due to the increasing prevalence of metabolic disorders across the globe. In addition, several risk factors like growing incidence of obesity, increasing unhealthy lifestyle, and presence of comorbidities is expected to boost the growth of metabolism drugs market. For instance, according to WHO, about 650 million people suffer from obesity in 2016 and is expected to increase more than four-fold times by 2030. In addition, increasing research and development along with the launch of new drugs by market players is expected to drive the market growth over the forecasted period.

Key Features of the Reports

  • The metabolism drug market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Metabolism Drugs Market Segmentation

By Therapy Type
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Drug Therapy 
  • Others
By Application
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

Metabolism Drugs market was valued at USD 7,098.9 million in 2022, and is expected to grow at a 5.4% CAGR from 2023 to 2029.

North America region is expected to hold a significant market share and dominate the metabolism drugs market over the forecast years.

The leading players in the global Metabolism Drugs market are Astra Zeneca, GlaxoSmithKline Plc, Novartis AG, Boehringer Ingelheim International GmbH, Amicus Therapeutics, Horizon Therapeutics, Takeda Pharmaceutical Company Limited, Sanofi, Merck Sharp & Dohme Corp, BioMarin Pharmaceutical.

Factors like side effects caused due to the prolonged treatment and regulatory policies and approvals of clinical trials is expected to hinder the market growth over the forecasted period.

  • Astra Zeneca
  • GlaxoSmithKline Plc
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Amicus Therapeutics
  • Horizon Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Merck Sharp & Dohme Corp
  • BioMarin Pharmaceutical